Q2 Earnings Forecast for Medpace Issued By Leerink Partnrs

Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) - Stock analysts at Leerink Partnrs boosted their Q2 2025 earnings per share estimates for Medpace in a research report issued to clients and investors on Tuesday, July 8th. Leerink Partnrs analyst M. Cherny now anticipates that the company will earn $2.93 per share for the quarter, up from their previous estimate of $2.76. Leerink Partnrs has a "Hold" rating on the stock. The consensus estimate for Medpace's current full-year earnings is $12.29 per share. Leerink Partnrs also issued estimates for Medpace's Q4 2025 earnings at $3.11 EPS and FY2028 earnings at $15.92 EPS.

Several other equities research analysts have also weighed in on MEDP. TD Cowen lowered Medpace from a "buy" rating to a "hold" rating and decreased their price objective for the stock from $370.00 to $328.00 in a report on Monday, April 14th. William Blair reiterated a "market perform" rating on shares of Medpace in a research report on Tuesday, April 22nd. Robert W. Baird reduced their price target on Medpace from $340.00 to $313.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 23rd. Mizuho reduced their price target on Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 9th. Finally, Barclays initiated coverage on Medpace in a research report on Tuesday, June 24th. They issued an "equal weight" rating and a $300.00 price objective on the stock. Twelve research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $344.82.

Medpace Stock Performance

NASDAQ:MEDP traded down $4.12 during trading on Thursday, reaching $324.12. The company's stock had a trading volume of 149,737 shares, compared to its average volume of 376,845. Medpace has a 12 month low of $250.05 and a 12 month high of $459.77. The firm has a 50 day moving average of $305.25 and a 200-day moving average of $318.99. The firm has a market cap of $9.32 billion, a price-to-earnings ratio of 24.74, a price-to-earnings-growth ratio of 5.77 and a beta of 1.47.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.06 by $0.61. The firm had revenue of $558.57 million during the quarter, compared to the consensus estimate of $528.38 million. Medpace had a return on equity of 54.36% and a net margin of 19.31%. During the same quarter in the prior year, the company earned $3.20 EPS.

Insider Transactions at Medpace

In other news, Director Fred B. Davenport, Jr. sold 1,712 shares of the business's stock in a transaction on Thursday, April 24th. The stock was sold at an average price of $301.82, for a total value of $516,715.84. Following the completion of the transaction, the director owned 2,998 shares in the company, valued at $904,856.36. The trade was a 36.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 20.30% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of MEDP. Mawer Investment Management Ltd. purchased a new position in shares of Medpace in the first quarter worth $212,131,000. Invesco Ltd. increased its position in Medpace by 91.8% during the fourth quarter. Invesco Ltd. now owns 1,084,753 shares of the company's stock valued at $360,387,000 after acquiring an additional 519,186 shares during the last quarter. Vulcan Value Partners LLC increased its position in Medpace by 221.6% during the first quarter. Vulcan Value Partners LLC now owns 325,916 shares of the company's stock valued at $99,159,000 after acquiring an additional 224,578 shares during the last quarter. Norges Bank purchased a new stake in Medpace during the fourth quarter valued at $69,859,000. Finally, Fundsmith LLP purchased a new stake in Medpace during the fourth quarter valued at $42,372,000. Hedge funds and other institutional investors own 77.98% of the company's stock.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.